Last reviewed · How we verify

PAL — Competitive Intelligence Brief

PAL (PAL) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical anti-inflammatory/analgesic. Area: Pain management; Dermatology.

marketed Topical anti-inflammatory/analgesic PPAR-α; endocannabinoid system Pain management; Dermatology Biologic Live · refreshed every 30 min

Target snapshot

PAL (PAL) — Folia Biotech Inc.. PAL is a topical palmitoylethanolamide (PEA) formulation that modulates endocannabinoid signaling to reduce inflammation and pain.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PAL TARGET PAL Folia Biotech Inc. marketed Topical anti-inflammatory/analgesic PPAR-α; endocannabinoid system

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical anti-inflammatory/analgesic class)

  1. Folia Biotech Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PAL — Competitive Intelligence Brief. https://druglandscape.com/ci/pal. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: